 Biotechnology company BioNTech wants to build its successes in COVID-19 by developing the first vaccine for malaria based on an mRNA technology. The company aims to start clinical testing by the end of 2022. BioNTech says it is also exploring vaccine production in Africa as part of its efforts to build up manufacturing capacity on the continent. Our goal is to develop a vaccine which makes the malaria parasite visible and attackable by the immune system from the very beginning when it is most vulnerable. So we plan for success from the very beginning. The second goal of our malaria project is to set up intelligence and sustainable mRNA manufacturing sites using modern digital technologies. This objective is part of our overall strategy to enable people around the world to manufacture our vaccines. Why now? Well because the time is right, the response to the pandemic has shown that science and innovation can make a difference when stakeholders work together towards a common goal and with joint willpower. But as it's already been said, it would be wonderful to have a vaccine with a stronger platform, more effectiveness, more efficiency and here we are today with BioNTech to announce a project on the deployment of mRNA technology to develop and produce a malaria vaccine in Africa. And I think this really is a historic moment. We may look back at this moment and see it as a transformative pivot point in the fight against malaria.